%& # & 6,7,/ =. % & 89 :65!! Hb 1 7D, = * 6*,&" name="description"> %& # & 6,7,/ =. % & 89 :65!! Hb 1 7D, = * 6*,&">

! **, ( -#. /) )* + ( ' ) "# $% 0 1% : 65! : 62 / : 62 7! 8 92"

Size: px
Start display at page:

Download "! **, ( -#. /) )* + ( ' ) "# $% 0 1% : 65! : 62 / : 62 7! 8 92""

Transcription

1 (%*) %&( %&'!"#$! **(,-#./) )* +*(') "# $%!" #$ % * $ '(' & ** 01%.!" # $ % & :23 / % 012.-% ()*. /,- ()* +!".7 % 612 # $ % &? %*:2 ; % % </ =; > %& # & 6,7,/ =. % & 89 :65!! Hb 1 7D, = * 6*,& 3,/ 6*,.- 7F,? < #2!/ TG,.LDL E%* QRS T2 >, S / < D 3, (K?/8O 2 %NN 2 1 %9H) K /H Hb 1 G; :62/ %N/9 3, % Hb 1 X. 2, Hb 1 K U/U8 ()* 6+ (p=u/uuv)? 2 1 %9H) ()* Y 9/8N EF 6* 3 / %&. (432 %N) K U/8? 2, Y / 3,.(P< U/UUUH) 3,/ 6* & ( %8N / 6* (Y ()* (kg O/HV 2 /H L %9H) #!/ 8/UV /% 6* 2 / %&./ D (/ (Y /9 2 /?O L %9H).S %=,!2 LDL E#2!/ 4T2 Z[.S %= 432 / / D T2-2, 6+ Hb 1 (/ K N/V \] 3 / *^ :627! 892".-% 612 # $ % & 5_ %F&/ > 3. < 6 &/ %8N

2 234 /...+#, -%.% /!" )*% 65!! 23 & : X- =; & 8U gy -, QRS2 %7 8U = / % NU &/ Y! Y. %N 2f < Hb 1-2f < cr / %& E- %7! Y : / % >/f [ ; / %& /H -d / op (OPD EHF E!/ E+/ &) l) & (/ (E?EE9E) 3 F-)D %m= (HEOE9EE).6,- $ 6 / & %R ] (NEEV)./% SD # 612 % & / *^ (/ E 2 / \] ef &Y.-% (/ / % 612 # $ % & % 2 / /.b,/ HU & bqy %!+ 4=; r.- :,- # ; X- / %&, 6^ d sd block randomization 2 3,/ 6* S* E E.* Hb ?EOEVE?EE?O 3.-, =, r ELDL Ehols ETG E% = Eg / o-.-, =; j2d :2) & - )q2 % %! HUU a 3 1+K = a t: 3 3, / 6* 1+K = a > # 3 1+K = a >) UUUmg/d # 3 # 3 / D ()* (#- = a > (d",] sd a >) HUUmg.- / D ()* )D.- % % g&12 6) u3 bf- Ev3 $2 gw %&h[] %!k g&12 w/y &.- % %-%. 3?O2 V (HUUmg) w/y./% :! ;<! x. %=+p Z g+ / -% & - %&!k bc.6 2`- ar- # $ 6 / SR% + / (/ %d" -%& gky %d" bc 2 ef&= <, 4+/2 99H 2.6 %!",< D %/ 2, g3 (E?E8) % 6F- %f ) 4+/2. F < 7 %/ / *^!" ()* % & =2.6 / E- % # - (HEO) f <, ()* \] / -% ()* \].- % F < 99H % > E 3.6* i2, gh3,& 2 / )cf! )cj/! 3 5 %!K bf %;1 * 6Y ()* (UE9EVENEE8) +/, %2 3 /.-% (NEE8E?E) # $ 6 & /, g3 a: ()* (E9E?E).6,SR 6,/ D + 3!2k

3 "#$/ "*" 8#%, ! "#$ (Fisher s exact test: p= 1.0) %&' (# "#$ #( )* +,-./ (Non-paired t-test: p= 0.71) X D 4T2, S 8?. 6, =, (- =; Hb 1.% S, 4T2 O. QRS (/ > 3, =; D, FY % S Hb 1 X.-%&,S %:RS T2 2 O 1+K = 6]? E- =../ / y= /%2K.- % % 6) UU & d" = VU & - 6- %2] (/ - f - /%2K./% D (/ D ()* U f d" = OU./% ; = %&.- SD & #&2 dt2,s #q.-, & % & d" %!/ %F)* 6=* =;, p - 6 & >?> 6 2/ -#' t!r, ` s D :wilcaxon rank-sum TesTs, ) )< / U/UH &/ P Value.- % (ontingency-table )* # )< #&2.- %!2 6& < z.- % Spss 6^ d sd -, 4][p &,qd.* 2 3, %*:2 p = (2, &?H) & HU D 4:RS.- 7D 3?O 4,/ /.6, < O 2.? & & E E Es. E% z,!2 LDL E22!/ Hb 1, 3 H, 3 ) &.- 7D 6. 3.F g / =; ( 3 ZdY =; g!12 )q2 g+ F =..-

4 239 /...+#, -%.% /!" )*% (# ( #( 0 # #( &67 8./ P-value* U/V? U/?V U/? U/?U U/O8V U/VUV U/88U U/UN # $% U/8 98/N N/9 U/ O/? /O /H9 /VU V/H 9/H?U9/N??8/? V9/V??/N OH/O 8V/V 9/O8 U/?9 NU/UV N/V9!" O?U OHN OH 8? NN V?/V O/U V/U V?/U V V NN 9 8U 8U N/8 /V H?/H OO/U FS (mg/dl) S (4pM) (mg/dl) (Y) Hblc (g/dl) (#!/) N? /U N/V 8OU N9 (mg/dl)!2 /V N/O?VH 89/H?UN/H?U 8 (mg/dl) 22!/ V/9??H/? O8?N/8?H/? H NU LDL (mg/dl) 8H/ OO/??8? O? U? /,! "#$ %& ' ()*& +,-./ "526 ;: #9 05' P-value* U/UU U/NN U/UV U/UU U/??V U/N U/8U U/HVV *: Paired t-test # $% U/8 O/N N/9 H9/8 O/? O/9 /H9 /?N V/H N/NU?U9/N O/U V9/V VU/V OH/O 8V/V 9/O8 N/9 NU/UV N?/UV!" O?U?8H OH 8U NN V?/V U/ V/U VV/U V 9 NN U9 8U N/8 H/9 H?/H HO/U & VU VU VU VU VU FS (mg/dl) S (4pM) (mg/dl) (Y) Hblc (g/dl) (#!/) N? /U N/V 8OU N9 (mg/dl)!2 /N HH/V 88U NN VU 89/H?UN/H?U 8 (mg/dl) 22!/ 88/9?U/8?VH OV VU?N/8?H/? H NU LDL (mg/dl)?o/o?v/? VV 98 VU

5 "#9/ "*" 8#%, /,! "#$ %& ' ()*& +,-./ "526 7 P-value* U/UON U/8U U/UUUH U/9O8 U/UUUH U/?N U/?O9 U/U8 *: Paired t-test # $%!" & 98/N??8/? OHN V FS (mg/dl) H8/O 8/8?HV 9U VU U/ H/U /O O/N /VU /H??/N?8V/8 8V/V OV/? U/?9 U/8? 8? OH V V O/U 8/V 9 ON 8U?N /V /? VU VU VU S (4pM) (mg/dl) (Y) Hblc (g/dl) 9/H N/V9 V?/U OO/U (#!/) 9/ON NU/9N U,V OV/U VU /V VO/V V/9 OV/9 8H/ 8O/9 N/O 9O/8??H/??/9 OO/? 8?/O?VH OU O8 88O?8??? N O? O U? NH VU VU VU (mg/dl)!2 (mg/dl) 22!/ LDL (mg/dl) %9H) #!/ 8/UV 2,.(P=U/U?V) ()* / / D ()* (#!/ O/HV 2 /H cl 432 (P< U/UUUH) % S %=.(P=U/9) S %=, 6 DEF =; &[D j2dk k G; V/N 22!/ 3,. S, (P=U/8)./ D (/ (/?V 2 cl %9H) mg/dl cl %9H) 8mg/dl 22!/ 2, Z[ (P=U/?O) / D (/ (N/8 2 }U/V 3, LDL S %= =; D,.(P=U/HV) S ()* ( 2 cl %9H) O mg/dl?u} (?O 2 cl %9H)? mg/dl LDL NO/U} 2,, Z[ (P=U/U)./ D (/ X ) 3,.+ %= ) LDL (/ (8N/H? 2 }U/?N cl %9H)?mg/dl!2.6* 2 D %N 3, Hb 1 G; X 2,, < 6 Hb 1 (/ X.6* (/, -.(P=U/O) + %=, 2 2:! : % 6* NPH? & #&2 NPH?,& & w/././%,3 ) Regular 6* 3 / %&.6* (/ (Y /V 2 /?O cl %9H) Y / / 2,/ 6*, FY./ D ()* (Y? 2 cl%9h) Y 9/8 =; D 2,.(P< U/UUUH) 3,/ 6*, ( %8N :!.- =; S MI, 8/8 2 U/? cl %9H) #!/ /V 3, %= T2 / / D ()* (#!/

6 233 /...+#, -%.% /!" )*% (# ( #( 5 <= >12 4 5&67./ 8 P-value* # $% # $% U/O8 NU/H }V/H??N/V }??/HH FS U/9 /NO 8O/N H?/UV V/98 S (4pM) <U/UUUH O/8?O/OH?N/HU }8/?H U/UUV??/U?/NN /U }O/9? Hb1c U/??? O/O O/NN H/UU?/V U/UV HH/8?/9U 8N/HN }H/UU!2 U/9V?O/O8 }?/?H?N/ /UV 22!/ U/U9H 9/8V }N/8 8U/NH N/9U LDL ) 3, Hb 1. QRS < %F&/ 3 % (</O%) <, G;.-% / + %& &/ (/ 2, Hb 1 T2 #] 7 4=; 6+ 3, Hb 1 h[] - =; / #] %- 2% =;,-,3 3 &/ < 7 g 2 % q w/y (HUUmg/dl).- =; Hb 1 &/ (/ %?O/H 2, 3, FY / D ()* (9/8u/d), S / % S (/ (/u/d) %8,& (/ -%, QRS < w 5i2, S 3, Hb 1 (/ %?H/V (/ > (8) F& D.-% 3 $ 6 & (U) F& [.,/ l) 3 )* (/ 22 (?) Eviles, Sant, Raskin, Sinding 3 )* %?O %?H ~ /./ l) Type 2 6 & +,& ()*.-% =; q S & =; ()*.6 `- /,& / & (N),/ 6* 6* (?E?H) troglitazone (?OE?8), g3.6,- l) /%!2 2, FY (P=U/N), Z[ (P=U/?N). S ()* 8mg/dl.(P=U/UV) - %= >) H* ), F & F.2 F&, %&!k ) 0 % - %7 3,/ Z: & 8 2.S %R, 2 3/ 3 / %/-./ g&12 I F!&] 3 5i2 =; & 6+ %;1 6Y (?EUE9ENEE) # $ 6 (?) > $ 6 # $ 6 & 3 5i2. #!= 3 /.6, 2QRS 3 / %!+ 412 =;.6./% i2 QRS + 3,/ 6*, / (/ K /H 3,/ 6*,.6 - T2 2, FY. S Hb 1 %!+ 4=; &/ (/.S, %:RS &/ %N Hb 1 3,. (?EU) % z e[ / (/ / 2,

7 "#>/ "*" 8#%, Hb 1 (/ \] 3 / *^, ( %N/ V / 6+ &/ ()* &/ %8N.- gky 2, #!/ /V 3, =; & % S ()* #!/ 8 2 /, S &/ ()*,/ 6*.+ QRS z T2 1. Dagogo-lack S, santiago jv. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. rth Intern med 1997; 157: Melander. oral antidiabetic drugs an overview. Diabetes med 1996; 13(9 suppl 6): s Scheen. Drug treatment of non-insulin dependent diabetes mellitus in the 1990 chievements and future developments. Durgs. 1997, 54: braira, owell, Nuttal FQ, Nagel N, onstock P, etal. Veteran affairs ooperative Study on glycemic control and complication in Type II diabetes (V SDM). Results of the feasibility trail. Veterans ffairs cooperative study in Type 2 diabetes. Diabetic care. 1995; 18: Herny RR, Gumbiner, Dizeler T, wallace P. lyon R, Gluaber HS Intensive onventional insulin therapy for type2 diabetes. Metabolic effects during a 6 mo outpatient Trail. Diabetes care. 1993; 16: ailey. Turner R. Metformin N Engl med: 1996; 334; Sirtory RS, pasik. Re-evaluation of a biguanide, metfomin. Mechanism of action and tolerability. Pharmacol Res 1994, 334; Davidson M, Peters L. n overview of metformin in the treatment of type 2 diabetes mellitus. m med 1997: Grarber, Duncon TG, Goodman M, mills D, Rohlt L. Double blind, placebo- ontrolled, dose-response trail. m of med 1997:102:494-7 in glycamic control and reduction of metabolic risk factors. Eur clin phrmacol. 1993; 44: Giugliiano D.Quatraro, cosol: G, minei, ceriello et al. metformin for obese, insulintreated diabetic patients. 11. Defronzo R, Goodman M. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. The Multicenter metformin Study Group. N Engle med: 1995, 333: Lefebure P, scheen. Improving the action of insulin. lin invest med. 1995; 18: b Pagano G, Tagliaferro V, carata Q, aselle MT, ozzoc, uitellif, et al. Metformin reduces requirements in type 1 (insulin-dependent)diabetes. Diabetologia 1983; 24:

8 23: /...+#, -%.% / 14. Defronzo R, arzilai N, Simonson D. Mechanism of metformin action in obese and lean non insulin-dependent diabetic subject. Sclin Endocrinol metab. 1991; 73: United Kingdom Prospective Diabetes Study 24:6-year, randomized, control trail comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed Type2 diabetes that could not be controlled with diet Therapy. United Kingdom Prospective Diabetes study grou. nn intern med. 1998; 128: Scheen, letiexhe MR, Letebure P. Effects of metformin in obese patients with impaired glucose tolerance. Diabetes Metab Rev. 1995; 11: Effect of intensive blood-glucose control with metformin on complications in overweight patients ith Type2 diabetes (UKPDS). UK prospective Diabetes Study (UKPDS) GROUP. Lancet: 1998; 325: Laissa viles-santa, MD; oyce sinding, MSN, RN; and philip Raskin, MD. nn Intern Med. 1999; 131: ergenstal R, ohnson M, whipple D, Nolle D, oycek, Roth L, et al. dvantages of adding metformin to multiple dose in insulin therapy in type 2 diabetes.!" )*% 20. Gigliano Quatraro, onsoli G, Minei, eriello, De Rosa N, etal Metformin for obese insulin treated diabetic Patients; improvement in glycemic control and reduction of metabolic risk factors, Eur ckin Pharmacol. 193; 44: viles-sant, sinding, Raskin P. The effects of metformin in poorly controlled insulin-treated type 2 diabetes mellitus. [bstract]. Diabetes. 1998; 47(suppl(1): International Diabetes Federation ongress, November 5-10, 2000, Mexico city, Mexico. 23. ahnson L. Wolf sl, kababi um. Efficacy ot insulin and suftonglurea combination therapy in Type 2 diabetes. meta-analysis of randomized placebo-ontrolled trials. rch Inten Med. 1996; 156: Halimi S, corticelli P,enhamou PY. ombination of insulin and snlfonyfureas. literature review. m Med Dogogo-ack S,Santiago V. Pathopysiology of type 2 diabetes and modes of action of therapeutic interventions. rch Intern Med. 1997; 157: Saltil R, Olefski M. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996; 45:

Combined Therapy with Insulin Plus Oral Agents. Is there Any Advantage?

Combined Therapy with Insulin Plus Oral Agents. Is there Any Advantage? Combined Therapy with Insulin Plus Oral Agents Is there Any Advantage? Matthew C. Riddle, M.D. Professor of Medicine Oregon Health & Science University Portland, Oregon Is there Any Advantage in Combined

More information

Metformin: Its Non-Glycemic Effects and Cardiovascular Risk Reduction. J. M. Miles, MD

Metformin: Its Non-Glycemic Effects and Cardiovascular Risk Reduction. J. M. Miles, MD Metformin: Its Non-Glycemic Effects and Cardiovascular Risk Reduction J. M. Miles, MD Case Study 73 y. o. woman, followed closely for Type 2 DM of 25 y duration. She has NYHA class 3 CHF. Echo shows HFpEF

More information

Does Diabetes Control Matter?

Does Diabetes Control Matter? Does Diabetes Control Matter? Laurence Kennedy, MD, FRCP Endocrinology Department Cleveland Clinic, OH Disclosures None Does Diabetes Control Matter? Generality of patients Relative Risk Complications

More information

Diabetes: An Introduction. UT Health Science Center

Diabetes: An Introduction. UT Health Science Center Diabetes: An Introduction UT Health Science Center DIABETES MELLITUS A metabolic disorder with multiple causes characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein

More information

Oral Hypoglycemic Agents and Heart Disease

Oral Hypoglycemic Agents and Heart Disease Oral Hypoglycemic Agents and Heart Disease Marwan Hamaty, MD, MBA Endocrinology and Metabolism Institute Cleveland Clinic Foundation Cleveland, OH Disclosures None to Disclose Objectives Review cardiac

More information

SLOWING DISEASE PROGRESSION IN TYPE 2 DIABETES: LATEST ADVANCES. DR. C.F. OTIENO Dept. of medicine, U.O.N

SLOWING DISEASE PROGRESSION IN TYPE 2 DIABETES: LATEST ADVANCES. DR. C.F. OTIENO Dept. of medicine, U.O.N SLOWING DISEASE PROGRESSION IN TYPE 2 DIABETES: LATEST ADVANCES DR. C.F. OTIENO Dept. of medicine, U.O.N UKPDS: progressive hyperglycemia on monotherapy in type 2 diabetes HbA 1c (%) 10 9 8 Conventional

More information

Type II diabetes: How to use the new oral medications

Type II diabetes: How to use the new oral medications Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.

More information

Hypoglycemia as a risk factor for cardiovascular disease and mortality

Hypoglycemia as a risk factor for cardiovascular disease and mortality Hypoglycemia as a risk factor for cardiovascular disease and mortality Dong-Jun Kim, M.D.,PhD. Department of Internal Medicine, Inje University College of Medicine Hypoglycemia: the most important complication

More information

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.

More information

Diabetes increased 70% among people age in approximately the last decade

Diabetes increased 70% among people age in approximately the last decade Hypoglycemia: A Complication When Targeting Type 2 Diabetes Jeffrey S. Freeman DO FACOI Professor of Internal Medicine Chairman Division of Endocrinology and Metabolism Philadelphia College of Osteopathic

More information

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%

More information

Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes

Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH

More information

St. Michael's Hospital Research Ethics Board Guidance Document for Reviewing Clinical Trials in Diabetes

St. Michael's Hospital Research Ethics Board Guidance Document for Reviewing Clinical Trials in Diabetes St. Michael's Hospital Research Ethics Board Guidance Document for Reviewing Clinical Trials in Diabetes 1.0 Introduction This document provides guidance for members of the Research Ethics Board (REB)

More information

Jill Malcolm, Karen Moir

Jill Malcolm, Karen Moir Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are

More information

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL 464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT

More information

Virtual Mentor American Medical Association Journal of Ethics March 2009, Volume 11, Number 3:

Virtual Mentor American Medical Association Journal of Ethics March 2009, Volume 11, Number 3: Virtual Mentor American Medical Association Journal of Ethics March 2009, Volume 11, Number 3: 237-241. CLINICAL PEARL Type 2 Diabetes: Lifestyle Changes and Drug Treatment Natalie A. Brooks, PharmD More

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Review of Diabetes Therapies: Key Drivers of Disease Progression

Review of Diabetes Therapies: Key Drivers of Disease Progression Review of Diabetes Therapies: Key Drivers of Disease Progression David M. Kendall, MD Medical Director and Chief of Clinical and Professional Services Associate Professor of Medicine University of Minnesota

More information

The majority of patients destined to develop

The majority of patients destined to develop RATIONALE FOR DIFFERENT AND EFFECTIVE TREATMENT APPROACHES IN TYPE 2 DIABETES * Martin J. Abrahamson, MD ABSTRACT The most common cause of mortality in diabetes is macrovascular disease, specifically coronary

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Fifty years of type 2 diabetes clinical trials: a short review

Fifty years of type 2 diabetes clinical trials: a short review Principles and Practice of Clinical Research Journal http://ppcr.org/journal/home-current ISSN: 2378-1890 Short Review Fifty years of type 2 diabetes s: a short review Thiago Bosco Mendes¹, Iago Navas

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

Diabetes Workshop. Type 1 Diabetic. In 2003 at age 42

Diabetes Workshop. Type 1 Diabetic. In 2003 at age 42 Diabetes Workshop September 30, 2014 Mark Schutta, M.D. G. Clayton Kyle Associate Professor of Diabetes Medical Director Penn Rodebaugh Diabetes Center Division of Endocrinology, Diabetes and Metabolism

More information

MANAGEMENT OF HYPERGLYCEMIA IN THE NONCRITICAL CARE SETTING

MANAGEMENT OF HYPERGLYCEMIA IN THE NONCRITICAL CARE SETTING MANAGEMENT OF HYPERGLYCEMIA IN THE NONCRITICAL CARE SETTING 1 RECOGNITION AND DIAGNOSIS OF HYPERGLYCEMIA IN NONCRITICALLY ILL PATIENTS 2 RECOGNITION AND DIAGNOSIS OF HYPERGLYCEMIA AND DIABETES IN THE HOSPITAL

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

Diabetes Medications in CKD. Dr Adam White, MD FRCPC Endocrinology and Metabolism UBC and SPH Division of Endocrinology

Diabetes Medications in CKD. Dr Adam White, MD FRCPC Endocrinology and Metabolism UBC and SPH Division of Endocrinology Diabetes Medications in CKD Dr Adam White, MD FRCPC Endocrinology and Metabolism UBC and SPH Division of Endocrinology Objectives Broadly review the current agents used for glycemic management in Type

More information

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of

More information

Comparative study of insulin glargine and NPH insulin in poorly controlled type 2 diabetic patients on OHA

Comparative study of insulin glargine and NPH insulin in poorly controlled type 2 diabetic patients on OHA Original article: Comparative study of insulin glargine and NPH insulin in poorly controlled type 2 diabetic patients on OHA Dr. Anurag Prasad,* Dr. Muzaffari Yasmeen,** Dr. Suchitra G Prasad,*** Dr. Md

More information

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control

More information

Randomized Trial of Fructosamine Home Monitoring in Patients with Diabetes. ) and can be monitored in the home. absolute decrease of HbA 1c

Randomized Trial of Fructosamine Home Monitoring in Patients with Diabetes. ) and can be monitored in the home. absolute decrease of HbA 1c ORIGINAL ARTICLE DIANA B. PETITTI, MD, MPH RICHARD CONTRERAS, MS Kaiser Permanente Southern California Research and Evaluation Pasadena, Calif JAMES DUDL, MD Kaiser Permanente Southern California Department

More information

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223- Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and

More information

120 RCTs Meta-analyses. Clinical trials. n (%) roportion. Before 1994

120 RCTs Meta-analyses. Clinical trials. n (%) roportion. Before 1994 Ovulation induction in PCOS: regimens with insulin sensitizers Stefano Palomba Department of Obstetrics & Gynecology University Magna Graecia of Catanzaro Catanzaro, Italy Why insulin sensitizers are effective

More information

Britni Hebert, MD PGY-1

Britni Hebert, MD PGY-1 Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,

More information

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children

More information

Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach

Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND

More information

Agenda. LAF237 Oral DPP4 1 Inhibitor with Potential for Sustainable Diabetes Control LAF237

Agenda. LAF237 Oral DPP4 1 Inhibitor with Potential for Sustainable Diabetes Control LAF237 Agenda Disease background and unmet need LAF237 background and New MoA data LAF237 review of new phase IIb/III data Study 239 Phase III monotherapy (52 week) vs. metformin Study 2329 Phase III monotherapy

More information

Management of new type II diabetes diagnosis

Management of new type II diabetes diagnosis Management of new type II diabetes diagnosis Case 31yr old healthy black man who presents to clinic with polyuria and polydipsia, small amount of weight loss. Family history: DM in grandmothers Social

More information

Basal/Bolus Insulin: Better Pattern Control in Type 2 Diabetes. Kim L Kelly, PharmD, BCPS, FCCP, CDTC, CPC, CEC

Basal/Bolus Insulin: Better Pattern Control in Type 2 Diabetes. Kim L Kelly, PharmD, BCPS, FCCP, CDTC, CPC, CEC Basal/Bolus Insulin: Better Pattern Control in Type 2 Diabetes Kim L Kelly, PharmD, BCPS, FCCP, CDTC, CPC, CEC What we ll cover Basal Insulin Basal initiation Basal alone vs. biphasic vs. prandial alone

More information

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,

More information

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing

More information

Case Study. Case Study. Glycemic Control-2001 How Low Can You Go? Evidence for Glycemic Control- So What? Now What?

Case Study. Case Study. Glycemic Control-2001 How Low Can You Go? Evidence for Glycemic Control- So What? Now What? Age-Adjusted Prevalence of Diagnosed Diabetes per 100 Adult Population, by State, United States, 1994 Evidence for Glycemic Control- So What? Now What? 1994 Cindy Sayre, MN, ARNP University of Washington

More information

Diagnosis, classification and prevention of diabetes

Diagnosis, classification and prevention of diabetes Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3

More information

The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies

The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies CLINICAL DIABETES VOL. 18 NO. 2 Spring 2000 PRACTICAL POINTERS The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies Barbara A. Ramlo-Halsted,

More information

ű Ű ű ű ű űű ű ő ő ű ű ő ő ő Ű ű ő ő Ű ő ű ű ő ű ű Ű ű Ő ű ű Ő Ű ű ű Ű Ű ő ű Ű ű ű ű Ű Ű Ű ő ő ű ő ű Ű Ő ő ő Ő ő ű ő ő Ő ű Ű ű ő Ű Ő ű ő ő ű Ő Ű ű ő ő ő Ő Ű Ő ű ő ű ű Ű Ű ű Ű ű Ű ű Ű Ű ű ű ű Ő ŰŐ ő Ű ő

More information

3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico

3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico 3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico Recidive del diabete dopo terapia chirurgica La quantificazione

More information

UPDATE ON MANAGEMENT OF TYPE 2 DIABETES NEW AND OLD TREATMENT OPTIONS

UPDATE ON MANAGEMENT OF TYPE 2 DIABETES NEW AND OLD TREATMENT OPTIONS UPDATE ON MANAGEMENT OF TYPE 2 DIABETES NEW AND OLD TREATMENT OPTIONS Mayer B. Davidson, MD Professor of Medicine Charles Drew University & David Geffen School of Medicine at UCLA CURRENT AMERICAN DIABETES

More information

MANAGEMENT OF HYPERGLYCEMIA IN THE NONCRITICAL CARE SETTING

MANAGEMENT OF HYPERGLYCEMIA IN THE NONCRITICAL CARE SETTING MANAGEMENT OF HYPERGLYCEMIA IN THE NONCRITICAL CARE SETTING RECOGNITION AND DIAGNOSIS OF HYPERGLYCEMIA IN NONCRITICALLY ILL PATIENTS 2 RECOGNITION AND DIAGNOSIS OF HYPERGLYCEMIA AND DIABETES IN THE HOSPITAL

More information

Reconciling Current Diabetes Guidelines

Reconciling Current Diabetes Guidelines Reconciling Current Diabetes Guidelines Jaime A. Davidson, MD, FACP. FACE Part 1. Diagnosis Welcome. I am Dr. Jaime Davidson, a clinical professor of medicine in the Department of Internal Medicine, Division

More information

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* 71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the

More information

Global Guideline for Type 2 Diabetes

Global Guideline for Type 2 Diabetes INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication

More information

Hyperglycemia and Diabetic Microvascular Complications (DMC)

Hyperglycemia and Diabetic Microvascular Complications (DMC) Hyperglycemia and Diabetic Microvascular Complications (DMC) Lois Jovanovic, MD CEO & Chief Scientific Officer Sansum Diabetes Research Institute Santa Barbara, California 1 Hyperglycemia and DMC: Outline

More information

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United

More information

Case Vignette for Question 5

Case Vignette for Question 5 Question 5: What are the options for intensifying therapy when basal insulin has not achieved target glycemia? Case Vignette for Question 5 64-year-old man with 9-year history of T2DM Current diabetes

More information

Controversies in Primary Care: Treating Pre-Diabetes

Controversies in Primary Care: Treating Pre-Diabetes Controversies in Primary Care: Treating Pre-Diabetes Disclosures I have no disclosures regarding the content of this lecture today. Kevin J. Goist, MD Assistant Professor of Clinical Medicine Lead Physician,

More information

Personalising metformin therapy : a clinician perspective

Personalising metformin therapy : a clinician perspective SHORT COMMENT FOR THE LANCET DIABETES & ENDOCRINOLOGY Personalising metformin therapy : a clinician perspective André J. SCHEEN University of Liège, Division of Diabetes, Nutrition and Metabolic Disorders

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow

More information

Type 2 Diabetes Media Fact Sheet

Type 2 Diabetes Media Fact Sheet Type 2 Diabetes Media Fact Sheet 1. Type 2 diabetes: Facts & figures 2. What is type 2 diabetes? 3. Risk factors for type 2 diabetes 4. Complications associated with type 2 diabetes 5. The socio-economic

More information

Evolving Trends and Strategies in the Treatment of Type 2 Diabetes

Evolving Trends and Strategies in the Treatment of Type 2 Diabetes Evolving Trends and Strategies in the Treatment of Type 2 Diabetes Kenneth Snow, MD Age adjusted Prevalence of Obesity and Diagnosed Diabetes Among U.S. Adults Aged 18 Years or Older Obesity (BMI 30 kg/m

More information

A1c and Estimated Average Glucose: From Diagnosis to Management

A1c and Estimated Average Glucose: From Diagnosis to Management A1c and Estimated Average Glucose: From Diagnosis to Management Where Do We Stand in 2011? David M. Kendall, MD Chief Scientific and Medical Officer American Diabetes Association Associate Professor of

More information

Controlling Diabetes: Successfully Using Oral Agents, Insulins,, Exenatide and Pramlintide

Controlling Diabetes: Successfully Using Oral Agents, Insulins,, Exenatide and Pramlintide Controlling Diabetes: Successfully Using Oral Agents, Insulins,, Exenatide and Pramlintide C. W. Spellman, Ph.D., D.O. Assist Dean, Dual Degree Programs Assoc. Prof. Medicine Head, Endocrinology and Dir.

More information

Use of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians

Use of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians Original Article Use of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians A Ramachandran, C Snehalatha, J Salini, V Vijay Abstract Aim : Short-term efficacy of

More information

Finding weight loss strategies that work in primary care

Finding weight loss strategies that work in primary care Finding weight loss strategies that work in primary care Article: Wilson C. Obesity: Finding weight loss strategies that work in primary care. Nat Rev Endocrinol. 2013;9(3):126. Review: In this Research

More information

( Self-measurement of blood glucose, SMBG )

( Self-measurement of blood glucose, SMBG ) 2006 17 123-127 ( Diabetes mellitus ) ( Continuous glucose monitor system, ) ( Self-measurement of blood glucose, SMBG ) DCCT(Diabetes Control and Complications Trial ) UKPDS ( U.K. Prospective Diabetes

More information

S. A. Schreiber 1 and T. Haak 2. Introduction

S. A. Schreiber 1 and T. Haak 2. Introduction ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2006.00593.x Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday

More information

A Pediatrician s Perspective of the Current State of Diabetes Management

A Pediatrician s Perspective of the Current State of Diabetes Management A Pediatrician s Perspective of the Current State of Diabetes Management Desmond Schatz, MD Professor of Pediatrics Medical Director, Diabetes Center University of Florida Financial Disclosure There are

More information

Severe Hypoglycemia in Type 2 Diabetes. A Hospital-based Retrospective Study

Severe Hypoglycemia in Type 2 Diabetes. A Hospital-based Retrospective Study 2006 17 73-77 Severe Hypoglycemia in Type 2 Diabetes A Hospital-based Retrospective Study Ya-Chun Hsiao, and Ming-Nan Chien 1 Division of Endocrinology and Metabolism, Department of Internal Medicine Mackay

More information

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence

More information

Objectives. Diabetes Today: An Epidemic NICE-SUGAR: 11/27/2013. In-Patient Diabetes Technology. Hyperglycemia Is Prevalent at Hospital Admission

Objectives. Diabetes Today: An Epidemic NICE-SUGAR: 11/27/2013. In-Patient Diabetes Technology. Hyperglycemia Is Prevalent at Hospital Admission In-Patient Diabetes Technology Dosing Applications, IV insulin Dosing Calculators, Animated Insulin Teaching Tools Objectives Present a free application available for calculating insulin doses for patients

More information

Prevention of type 2 diabetes: Making the evidence work in the UK. Bernie Stribling and Dr Tom Yates

Prevention of type 2 diabetes: Making the evidence work in the UK. Bernie Stribling and Dr Tom Yates Prevention of type 2 diabetes: Making the evidence work in the UK Bernie Stribling and Dr Tom Yates Aims of the presentation Structured education in the prevention of diabetes The PREPARE and Walking Away

More information

Which drugs should be used to treat diabetes in cirrhotic patients?

Which drugs should be used to treat diabetes in cirrhotic patients? Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance

More information

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2

More information

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received

More information

Diabetes Complications

Diabetes Complications Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation

More information

LIFESTYLE CHOICES FOR PREVENTION AND INTERVENTION IN DIABETES. Gregory Hand, PhD MPH School of Public Health West Virginia University

LIFESTYLE CHOICES FOR PREVENTION AND INTERVENTION IN DIABETES. Gregory Hand, PhD MPH School of Public Health West Virginia University LIFESTYLE CHOICES FOR PREVENTION AND INTERVENTION IN DIABETES Gregory Hand, PhD MPH School of Public Health West Virginia University LEARNING OBJECTIVES Participants will review the epidemiological evidence

More information

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than

More information

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC.

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association

More information

Pathophysiology of Type 2 Diabetes and Its Treatment Policy

Pathophysiology of Type 2 Diabetes and Its Treatment Policy Research and Reviews Pathophysiology of Type 2 Diabetes and Its Treatment Policy JMAJ 53(1): 41 46, 2010 Kohei KAKU* 1 Abstract Impaired insulin secretion and increased insulin resistance, the main pathophysiological

More information

Glycemic Control and the Impact on CVD Risk in Diabetes

Glycemic Control and the Impact on CVD Risk in Diabetes Glycemic Control and the Impact on CVD Risk in Diabetes The Case for Intensive Glucose Control David M. Kendall, MD Chief Scientific and Medical Officer Glucose and CVD Risk: From UGDP to ACCORD Glycemic

More information

Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes

Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,

More information

Key words: Metformin, Diabetes, Adverse drug reactions, Tertiary care hospital.

Key words: Metformin, Diabetes, Adverse drug reactions, Tertiary care hospital. Explor. Anim. Med. Res., Vol.3, Issue - 2, 2013, p. 117-122 ISSN 2277-470X (Print), ISSN 2319-247X (Online) Website: www.animalmedicalresearch.org INVESTIGATION OF ADVERSE DRUG REACTIONS RELATED TO METFORMIN

More information

Question 3: What are the new and emerging basal insulins and their features?

Question 3: What are the new and emerging basal insulins and their features? Question 3: What are the new and emerging basal insulins and their features? Case Vignette for Question 3 62-year-old white female with T2DM for 8 years Current diabetes medications: Metformin 1000 mg

More information

Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes

Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes William B. White, MD for the EXAMINE Investigators Cardiology Center, University of

More information

GLP-1 Receptor Agonists (Byetta /Victoza ) Step Therapy Criteria

GLP-1 Receptor Agonists (Byetta /Victoza ) Step Therapy Criteria GLP-1 Receptor Agonists (Byetta /Victoza ) Step Therapy Criteria Brand Generic Dosage Form Byetta exenatide subcutaneous injection Victoza liraglutide subcutaneous injection PROGRAM OBJECTIVES The intent

More information

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word

More information

Diabetes and ramadan. K. Abdallah (Egypt)

Diabetes and ramadan. K. Abdallah (Egypt) Diabetes and ramadan K. Abdallah (Egypt) Diabetes and Ramadan Khalifa Abdallah Professor of Internal Medicine Unit of Diabetes & Metabolic Diseases Alexandria Faculty of Medicine Istanbul 9 MAY 2015 Disclosure

More information

4/13/2016. Strategies for Effective Discharge Planning for Hospitalized Patients With Diabetes. Disclosures. Objectives

4/13/2016. Strategies for Effective Discharge Planning for Hospitalized Patients With Diabetes. Disclosures. Objectives Strategies for Effective Discharge Planning for Hospitalized Patients With Diabetes 1 Disclosures I do not have any conflicts of interest or financial disclosures To receive contact hours for this continuing

More information

Diabetes is a. A case for prevention of type 2 diabetes mellitus

Diabetes is a. A case for prevention of type 2 diabetes mellitus A case for prevention of type 2 diabetes mellitus Joseph Cook, DO Diabetes is a disease that has reached epidemic proportions in the United States and around the world. This is troubling because, as bad

More information

This article is a CME certified activity. To earn credit for this activity visit:

This article is a CME certified activity. To earn credit for this activity visit: This article is a CME certified activity. To earn credit for this activity visit: http://cme.medscape.com/viewarticle/707234 cme.medscape.com From MedscapeCME Family Medicine > Best Evidence Review Metformin

More information

Type 2 Diabetes Mellitus Incretin Based Therapy

Type 2 Diabetes Mellitus Incretin Based Therapy Type 2 Diabetes Mellitus Incretin Based Therapy Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Type 2 Diabetes Mellitus

More information

International Journal of Pharma and Bio Sciences

International Journal of Pharma and Bio Sciences International Journal of Pharma and Bio Sciences ASSESSMENT THE INFLUENCE OF PATIENT COUNSELING ON QUALITY OF LIFE IN TYPE-II DIABETES MELLITUS PATIENTS. SOURAV GHOSH *, AJEET KUMAR RAJVANSHI AND SHRI

More information

The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014

The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014 Introduction The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014 The prevalence of type 2 diabetes is reaching epidemic proportions with more than 9.3% of adults in

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary

More information

SGLT2 Inhibitors Studied for A1C Lowering & Weight Loss in Type 2 Diabetes

SGLT2 Inhibitors Studied for A1C Lowering & Weight Loss in Type 2 Diabetes ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES MARCH 2015 Coverage of data from ENDO 2015, March 5 8 in San Diego, California SGLT2 Inhibitors Studied for A1C Lowering & Weight Loss in Type 2 Diabetes

More information

EFFICACY OF BARIATRIC SURGERY IN OBESE INDIAN WITH TYPE 2 DIABETES MELLITUS

EFFICACY OF BARIATRIC SURGERY IN OBESE INDIAN WITH TYPE 2 DIABETES MELLITUS EFFICACY OF BARIATRIC SURGERY IN OBESE INDIAN WITH TYPE 2 DIABETES MELLITUS Subodh Banzal, Abhishek Singhai, Mohit Bhandari, Padmnabh Sharma, Rajesh Kumar Jha, Piyush Manoria 1. Associate Professor, DM,

More information